Neoplasms Clinical Trial
Although Neopharm has terminated its sponsorship of this study, it is continuing under the
sponsorship of the NCI. Please see "Experimental Drug SS1(dsFv)-PE38 to Treat Cancer" (Study
ID number 010011).
SS1(dsFv)-PE38 is an oncology drug product containing a bacteria toxin, fused to a high
affinity, disulfide stabilized antibody. The fused protein retains cell killing activity,
but binds only to cells expressing mesothelin. Tumors characterized by very high surface
mesothelin expression include mesothelioma; epithelial carcinomas of ovary and peritoneum;
and squamous cancers of cervix and upper aerodigestive tract, including esophagus, head, and
neck cancers.
This is a dose-escalating study to determine the maximum tolerated dose (MTD) of intravenous
SS1(dsFv)-PE38 administered continuously for 10 days every four weeks for a maximum of four
courses of treatment. Dose escalation will proceed in cohorts of 3 until dose-limiting
toxicity (DLT) is observed.
OBJECTIVES: I. Investigate the safety and efficacy of SS1(dsFv)-PE38 administered as a
10-day continuous intravenous infusion.
II. Determine the toxicities and maximum tolerated dose (MTD) of SS1(dsFv)-PE38 given by
continuous intravenous infusion for ten days in patients with advanced malignancies.
III. Evaluate response of selected advanced malignancies to continuous intravenous infusion
of SS1(dsFv)-PE38 for ten days at doses near the MTD.
IV. Characterize the plasma kinetics of SS1(dsFv)-PE38 administered by continuous
intravenous infusion.
V. Determine the appearance of serum antibody to SS1(dsFv)-PE38.
PROTOCOL OUTLINE: To exclude immediate allergic hypersensitivity reaction, each patient will
receive a test dose of SS1(dsFv)-PE38, and be observed for 30 minutes prior to receiving the
continuous infusion on Day 1 of each treatment course. Each treatment will be given by
continuous intravenous infusion for ten days. After the first 24 hours of infusion, at the
Investigator's discretion, patients will be allowed to leave the hospital on day pass per
NCI policies. After the end of infusion patients will be observed overnight. The first
patient at each dose level must be observed for development of toxicity for at least 14 days
after the beginning of treatment before additional patients are enrolled. At least three
patients will be accrued at each dose level. Dose escalation within a patient will not be
allowed.
PROJECTED ACCRUAL: Up to 30 patients
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
| Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
| Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
| Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
| Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|